As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.
Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib’s efficacy
A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib
February 8, 2024